The Carlyle Group acquires minority share in Ambio from MVM Partners
12 September 2018 -

The Carlyle Group, a global alternative asset manager, has acquired a minority share in Ambio, a US-based global peptide active pharmaceutical ingredient (API) contract development and manufacturing organisation, from MVM Partners, a specialist healthcare fund, it was reported on Tuesday.

Carlyle received equity for the investment from Carlyle Asia Partners, while MVM retains a significant interest in Ambio.

The firm has also collaborated with major global pharmaceutical companies to develop generic peptides. It has two manufacturing sites in China and the US, employing more than 400 people. The Carlyle Group has invested more than USD11.5bn of equity in more than 65 transactions in the global healthcare industry as of June 30, 2018. In Asia, Carlyle has invested around USD1.5bn in 10 healthcare companies.